Drug Profile
Research programme: D-peptide therapeutics - Navigen
Alternative Names: D-peptideLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Navigen Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antivirals; Immunotherapies; Peptides
- Mechanism of Action Peptide inhibitors; SIRPA protein inhibitors; Tumour necrosis factor alpha inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Ebola virus infections; Inflammatory bowel diseases; Respiratory syncytial virus infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Nov 2023 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (PO)
- 28 Sep 2022 No recent reports of development identified for research development in Ebola-virus-infections in USA